Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TM5614 plus gemcitabine + nab-paclitaxel in metastatic unresectable or recurrent pancreatic cancer
jRCT2021260008Phase 2Recruiting
- Sponsor
- Because this is a physician-initiated clinical trial, there are no specific findings.
- Start
- May 2026
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TM5614 in pancreatic adenocarcinoma (PDAC) and pancreatic adenosquamous carcinoma (PASC), sponsored by Because this is a physician-initiated clinical trial, there are no specific findings. Primary endpoint: Objective response rate at 48 weeks. Started May 2026; status: recruiting.
02
Drugs
TM5614
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic adenosquamous carcinoma (PASC)
Beyond the preview
Go deeper on jRCT2021260008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260008.